Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd. has reported significant milestones, including positive clinical trial results for its anti-infective agent RECCE 327, successful expansion of clinical trials, and inclusion on the WHO’s list of antibacterial products in development. Financially, the company secured a substantial pro-forma cash position of A$16 million after an institutional placement and a Share Purchase Plan aimed at raising approximately A$10 million. Additionally, they received a A$2.6 million R&D Tax Incentive rebate from the Australian Tax Office.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
